IMMURON LIMITED - Announcements

Market Cap $20.52M Add to my watchlist

Healthcare Biotechnology

Immuron Limited is an Australia-based biopharmaceutical company focused on developing and... Immuron Limited is an Australia-based biopharmaceutical company focused on developing and commercializing orally delivered targeted polyclonal antibodies for the treatment of infectious diseases. It operates through two segments: Research and development (R&D), and Hyperimmune products. The R&D segment is focused on R&D projects in Australia, Israel and the United States. The Company's flagship commercial products consist of Travelan and Protectyn. Travelan is an over the counter orally administered passive immunotherapeutic product indicated to reduce the risk of travelers' diarrhea, reduce the risk of minor gastro-intestinal disorders and is antimicrobial. Protectyn is sold online and in health practitioner clinics and is marketed as an immune supplement to help maintain a healthy digestive function and liver. The Company has four clinical programs -Travelan (IMM-124E), CampETEC, IMM-529 and Travelan (consumer product).More

Announcements

Filter Results

All Price Sensitive Only

Filters [Clear]

Price Sensitive: Yes

IMC	Immuron Travelan sales continued strong growth	PRICE SENSITIVE	10/04/24	315.78KB	Share
IMC	Travelan to progress to Phase 3 Clinical Trials in the US	PRICE SENSITIVE	07/03/24	408.71KB	Share
IMC	Trading Halt	PRICE SENSITIVE	05/03/24	221.96KB	Share
IMC	Appendix 4D and Half Year Report	PRICE SENSITIVE	28/02/24	2.93MB	Share
IMC	Immuron achieves record Travelan sales	PRICE SENSITIVE	13/02/24	260.27KB	Share
IMC	Immuron achieves record half yearly Travelan sales	PRICE SENSITIVE	16/01/24	277.27KB	Share
IMC	First Patients Enrolled in Campylobacter Clinical Study	PRICE SENSITIVE	04/12/23	303.92KB	Share
IMC	Immuron achieves record quarterly Travelan sales	PRICE SENSITIVE	11/10/23	279.1KB	Share
IMC	Immuron achieves record monthly Travelan sales	PRICE SENSITIVE	13/09/23	262.36KB	Share
IMC	Appendix 4E Preliminary Final Report	PRICE SENSITIVE	30/08/23	2.14MB	Share
IMC	Immuron Receives TGA GMP Clearance	PRICE SENSITIVE	09/08/23	277.95KB	Share
IMC	Immuron enrols patients in Travelan clinical study	PRICE SENSITIVE	25/07/23	303.58KB	Share
IMC	Immuron FY23 Sales increase 136% on FY22 Sales	PRICE SENSITIVE	05/07/23	280.73KB	Share
IMC	Immuron Initiates Recruitment of Travelan Clinical Study	PRICE SENSITIVE	30/05/23	297.14KB	Share
IMC	FDA Removed Clinical Hold on Campylobacter ETEC Therapeutic	PRICE SENSITIVE	08/05/23	295.07KB	Share
IMC	Q3 FY23 Business Update Presentation	PRICE SENSITIVE	19/04/23	866.7KB	Share
IMC	Immuron Q3 Sales reach 150% of 1H Sales	PRICE SENSITIVE	06/04/23	262.26KB	Share
IMC	Appendix 4D and Half Year Report	PRICE SENSITIVE	28/02/23	2.8MB	Share
IMC	Business Update Presentation	PRICE SENSITIVE	28/02/23	746.36KB	Share
IMC	Immuron Receives FDA Approval for Travelan IND Application	PRICE SENSITIVE	23/12/22	285.59KB	Share
IMC	Immuron completes strategic investment in Ateria Health	PRICE SENSITIVE	16/11/22	323.13KB	Share
IMC	IMC investment in leading gut health biotech Ateria Health	PRICE SENSITIVE	13/10/22	343.35KB	Share
IMC	Appendix 4E and Preliminary Final Report	PRICE SENSITIVE	31/08/22	1.46MB	Share
IMC	Immuron Update on IMM-124E SARS-CoV-2 Research	PRICE SENSITIVE	19/08/22	284.76KB	Share
IMC	North American Travelan Sales up 494%, Global sales up 431%	PRICE SENSITIVE	11/07/22	258.28KB	Share
IMC	European Patent Notification on Drug Composition for CDI	PRICE SENSITIVE	07/07/22	388.35KB	Share
IMC	US DoD NMRC files IND application with FDA	PRICE SENSITIVE	11/05/22	315.64KB	Share
IMC	US DoD Uniformed Services University Clinical Update	PRICE SENSITIVE	09/05/22	301.1KB	Share
IMC	Appointment of Mr Steven Lydeamore as Chef Executive Officer	PRICE SENSITIVE	05/05/22	292.96KB	Share
IMC	Immuron Q3 Global Sales up 216% YoY	PRICE SENSITIVE	27/04/22	267.71KB	Share
IMC	Half Yearly Report and Accounts	PRICE SENSITIVE	25/02/22	3.23MB	Share
IMC	Response to ASX Query	PRICE SENSITIVE	24/01/22	315.93KB	Share
IMC	Immuron Receives European Patent on Drug to Treat Diarrhea	PRICE SENSITIVE	13/01/22	301.66KB	Share
IMC	US DoD Travelan Clinical Update	PRICE SENSITIVE	15/11/21	296.3KB	Share
IMC	US DoD Naval Medical Research Center Clinical Update	PRICE SENSITIVE	10/11/21	319.57KB	Share
IMC	IMM124E Demonstrates Antiviral T-Cell Immunity	PRICE SENSITIVE	08/10/21	319.84KB	Share
IMC	Reinstatement to Official Quotation	PRICE SENSITIVE	23/09/21	88.02KB	Share
IMC	Immuron planned Acquisition of R&D Vaccine Company	PRICE SENSITIVE	23/09/21	308.02KB	Share
IMC	Preliminary Final Report	PRICE SENSITIVE	31/08/21	284.19KB	Share
IMC	Voluntary Suspension	PRICE SENSITIVE	31/05/21	201.01KB	Share
IMC	Trading Halt	PRICE SENSITIVE	27/05/21	263.01KB	Share
IMC	Pause in Trading	PRICE SENSITIVE	27/05/21	115.9KB	Share
IMC	IMM124E May Offer New Modality for Inhibition of SARS-CoV-2	PRICE SENSITIVE	13/05/21	1.08MB	Share
IMC	Half Yearly Report and Accounts	PRICE SENSITIVE	25/02/21	2.89MB	Share
IMC	Immuron SARS-CoV-2 Research Agreement with Monash University	PRICE SENSITIVE	15/12/20	297.8KB	Share
IMC	Immuron Receives AUD $358,280 R&D Tax Concession Refund	PRICE SENSITIVE	24/11/20	216.57KB	Share
IMC	US DoD NMRC Reports Positive Response to Vaccine	PRICE SENSITIVE	09/11/20	326.03KB	Share
IMC	Immuron Travelers Diarrhea Market Update	PRICE SENSITIVE	12/10/20	333.58KB	Share
IMC	Appendix 4E and 2020 Financial Report	PRICE SENSITIVE	01/09/20	3.17MB	Share
IMC	Immuron Announces US$20.0 Million Registered Direct Offering	PRICE SENSITIVE	22/07/20	286.41KB	Share
IMC	Immuron Reports Neutralizing activity Against SARS-CoV-2	PRICE SENSITIVE	21/07/20	307.03KB	Share
IMC	US DoD Receives FDA Guidance on clinical development plans	PRICE SENSITIVE	20/07/20	290.86KB	Share
IMC	IMC & CSIRO to produce oral therapeutic for DoD evaluation	PRICE SENSITIVE	19/06/20	328.83KB	Share
IMC	Response to ASX Price Query	PRICE SENSITIVE	10/06/20	327.98KB	Share
IMC	Pause in Trading	PRICE SENSITIVE	10/06/20	115.07KB	Share
IMC	Immuron Global Sales Up 60%	PRICE SENSITIVE	20/04/20	273.25KB	Share
IMC	Resignation of Managing Director and cuts amid Covid19	PRICE SENSITIVE	25/03/20	243.36KB	Share
IMC	Half Yearly Report and Accounts	PRICE SENSITIVE	26/02/20	2.53MB	Share
IMC	North American Travelan sales up 98% to Dec 2019	PRICE SENSITIVE	28/01/20	355.62KB	Share
IMC	Immuron Plans IMM-124E Trial to Prevent Travelers Diarrhea	PRICE SENSITIVE	21/11/19	256.63KB	Share
IMC	Immuron Receives AUD $0.53M R&D Tax Concession Refund	PRICE SENSITIVE	04/11/19	233KB	Share
IMC	Immuron North American Q1 Sales Up 111% YoY	PRICE SENSITIVE	14/10/19	273.95KB	Share
IMC	US Defense funds AU$5.5M for Immuron New Gastro Weapon	PRICE SENSITIVE	02/10/19	295.1KB	Share
IMC	US Defense Reports Immuron Travelan Targets Cholera	PRICE SENSITIVE	04/09/19	243.34KB	Share
IMC	Appendix 4E & Annual Report to shareholders	PRICE SENSITIVE	30/08/19	3.36MB	Share
IMC	Immuron Reports Results in SAH Clinical Trial	PRICE SENSITIVE	08/08/19	253.67KB	Share
IMC	Underwritten Public Offer	PRICE SENSITIVE	17/07/19	82.1KB	Share
IMC	Immuron Prices Underwritten Public Offering of ADSs	PRICE SENSITIVE	17/07/19	185.56KB	Share
IMC	Trading Halt	PRICE SENSITIVE	17/07/19	386.27KB	Share
IMC	Proposed Public Offer of IMRN ADSs	PRICE SENSITIVE	17/07/19	216.67KB	Share
IMC	Immuron North American revenue surges by 52% in FY19	PRICE SENSITIVE	16/07/19	271.01KB	Share
IMC	US DoD Reports Results from Travelan Shigellosis Study	PRICE SENSITIVE	12/06/19	243.46KB	Share
IMC	Underwritten Public Offer	PRICE SENSITIVE	24/05/19	81.25KB	Share
IMC	Preliminary Prospectus Supplement filed with SEC	PRICE SENSITIVE	24/05/19	537.42KB	Share
IMC	Immuron Prices Underwritten Public Offering of ADSs	PRICE SENSITIVE	24/05/19	185.41KB	Share
IMC	Trading halt	PRICE SENSITIVE	24/05/19	249.9KB	Share
IMC	Proposed Public Offer of IMRN ADSs	PRICE SENSITIVE	24/05/19	188.83KB	Share
IMC	Immuron Appoints CEO Dr. Gary S. Jacob to Board of Directors	PRICE SENSITIVE	17/04/19	1.02MB	Share
IMC	Immuron sales surge by 66% in the Third Quarter of FY19	PRICE SENSITIVE	15/04/19	955.6KB	Share
IMC	Immuron Aims to Secure FDA Approval for IMM-124E	PRICE SENSITIVE	11/04/19	887.69KB	Share
IMC	Company Update on CDI Clinical Trial and New Strategic Focus	PRICE SENSITIVE	19/03/19	1.21MB	Share
IMC	Half Yearly Report and Accounts	PRICE SENSITIVE	28/02/19	872.79KB	Share
IMC	Travelan FY19 Update and Expansion into North America	PRICE SENSITIVE	29/01/19	950.8KB	Share
IMC	Form F-3	PRICE SENSITIVE	15/01/19	1.25MB	Share
IMC	Immuron Receives $1.19M R&D Tax Concession Refund	PRICE SENSITIVE	03/01/19	938.35KB	Share
IMC	IMC Appoints Experienced US Based Biotech Executive as CEO	PRICE SENSITIVE	19/11/18	1.08MB	Share
IMC	NASH clinical trial presentation & continued revenue growth	PRICE SENSITIVE	09/11/18	848.67KB	Share
IMC	US DoD Report Travelan Protects Against Shigella in Primates	PRICE SENSITIVE	05/09/18	1001.92KB	Share
IMC	Preliminary Final Report	PRICE SENSITIVE	30/08/18	239.38KB	Share
IMC	Immuron Reports Record Revenue	PRICE SENSITIVE	25/07/18	872.69KB	Share
IMC	US Department of Defense Research Collaboration Moves Ahead	PRICE SENSITIVE	16/07/18	881.93KB	Share
IMC	European Patent Gramted for Nash Treatment	PRICE SENSITIVE	11/07/18	782.89KB	Share
IMC	Immuron Announces Board Appointment	PRICE SENSITIVE	26/06/18	815.87KB	Share
IMC	Trading Halt	PRICE SENSITIVE	25/06/18	221.37KB	Share
IMC	IMC Preclinical Study Reports Reduction in Colitis Symptoms	PRICE SENSITIVE	08/05/18	960.7KB	Share
IMC	Travelan Sales Continue to Soar in Third Quarter of FY2018	PRICE SENSITIVE	23/04/18	369.02KB	Share
IMC	Immuron Announces A$5.1M Private Placement to U.S. Fund	PRICE SENSITIVE	14/03/18	362.89KB	Share
IMC	Immuron Progresses Discussions with Institutional Funds	PRICE SENSITIVE	13/03/18	349.77KB	Share
IMC	Trading Halt	PRICE SENSITIVE	12/03/18	215.65KB	Share
IMC	Immuron Reports Positive Results in NASH Clinical Trial	PRICE SENSITIVE	08/03/18	402.23KB	Share

IMC Immuron Travelan sales continued strong growth
10/04/24	PRICE SENSITIVE	315.78KB	Share
IMC Travelan to progress to Phase 3 Clinical Trials in the US
07/03/24	PRICE SENSITIVE	408.71KB	Share
IMC Trading Halt
05/03/24	PRICE SENSITIVE	221.96KB	Share
IMC Appendix 4D and Half Year Report
28/02/24	PRICE SENSITIVE	2.93MB	Share
IMC Immuron achieves record Travelan sales
13/02/24	PRICE SENSITIVE	260.27KB	Share
IMC Immuron achieves record half yearly Travelan sales
16/01/24	PRICE SENSITIVE	277.27KB	Share
IMC First Patients Enrolled in Campylobacter Clinical Study
04/12/23	PRICE SENSITIVE	303.92KB	Share
IMC Immuron achieves record quarterly Travelan sales
11/10/23	PRICE SENSITIVE	279.1KB	Share
IMC Immuron achieves record monthly Travelan sales
13/09/23	PRICE SENSITIVE	262.36KB	Share
IMC Appendix 4E Preliminary Final Report
30/08/23	PRICE SENSITIVE	2.14MB	Share
IMC Immuron Receives TGA GMP Clearance
09/08/23	PRICE SENSITIVE	277.95KB	Share
IMC Immuron enrols patients in Travelan clinical study
25/07/23	PRICE SENSITIVE	303.58KB	Share
IMC Immuron FY23 Sales increase 136% on FY22 Sales
05/07/23	PRICE SENSITIVE	280.73KB	Share
IMC Immuron Initiates Recruitment of Travelan Clinical Study
30/05/23	PRICE SENSITIVE	297.14KB	Share
IMC FDA Removed Clinical Hold on Campylobacter ETEC Therapeutic
08/05/23	PRICE SENSITIVE	295.07KB	Share
IMC Q3 FY23 Business Update Presentation
19/04/23	PRICE SENSITIVE	866.7KB	Share
IMC Immuron Q3 Sales reach 150% of 1H Sales
06/04/23	PRICE SENSITIVE	262.26KB	Share
IMC Appendix 4D and Half Year Report
28/02/23	PRICE SENSITIVE	2.8MB	Share
IMC Business Update Presentation
28/02/23	PRICE SENSITIVE	746.36KB	Share
IMC Immuron Receives FDA Approval for Travelan IND Application
23/12/22	PRICE SENSITIVE	285.59KB	Share
IMC Immuron completes strategic investment in Ateria Health
16/11/22	PRICE SENSITIVE	323.13KB	Share
IMC IMC investment in leading gut health biotech Ateria Health
13/10/22	PRICE SENSITIVE	343.35KB	Share
IMC Appendix 4E and Preliminary Final Report
31/08/22	PRICE SENSITIVE	1.46MB	Share
IMC Immuron Update on IMM-124E SARS-CoV-2 Research
19/08/22	PRICE SENSITIVE	284.76KB	Share
IMC North American Travelan Sales up 494%, Global sales up 431%
11/07/22	PRICE SENSITIVE	258.28KB	Share
IMC European Patent Notification on Drug Composition for CDI
07/07/22	PRICE SENSITIVE	388.35KB	Share
IMC US DoD NMRC files IND application with FDA
11/05/22	PRICE SENSITIVE	315.64KB	Share
IMC US DoD Uniformed Services University Clinical Update
09/05/22	PRICE SENSITIVE	301.1KB	Share
IMC Appointment of Mr Steven Lydeamore as Chef Executive Officer
05/05/22	PRICE SENSITIVE	292.96KB	Share
IMC Immuron Q3 Global Sales up 216% YoY
27/04/22	PRICE SENSITIVE	267.71KB	Share
IMC Half Yearly Report and Accounts
25/02/22	PRICE SENSITIVE	3.23MB	Share
IMC Response to ASX Query
24/01/22	PRICE SENSITIVE	315.93KB	Share
IMC Immuron Receives European Patent on Drug to Treat Diarrhea
13/01/22	PRICE SENSITIVE	301.66KB	Share
IMC US DoD Travelan Clinical Update
15/11/21	PRICE SENSITIVE	296.3KB	Share
IMC US DoD Naval Medical Research Center Clinical Update
10/11/21	PRICE SENSITIVE	319.57KB	Share
IMC IMM124E Demonstrates Antiviral T-Cell Immunity
08/10/21	PRICE SENSITIVE	319.84KB	Share
IMC Reinstatement to Official Quotation
23/09/21	PRICE SENSITIVE	88.02KB	Share
IMC Immuron planned Acquisition of R&D Vaccine Company
23/09/21	PRICE SENSITIVE	308.02KB	Share
IMC Preliminary Final Report
31/08/21	PRICE SENSITIVE	284.19KB	Share
IMC Voluntary Suspension
31/05/21	PRICE SENSITIVE	201.01KB	Share
IMC Trading Halt
27/05/21	PRICE SENSITIVE	263.01KB	Share
IMC Pause in Trading
27/05/21	PRICE SENSITIVE	115.9KB	Share
IMC IMM124E May Offer New Modality for Inhibition of SARS-CoV-2
13/05/21	PRICE SENSITIVE	1.08MB	Share
IMC Half Yearly Report and Accounts
25/02/21	PRICE SENSITIVE	2.89MB	Share
IMC Immuron SARS-CoV-2 Research Agreement with Monash University
15/12/20	PRICE SENSITIVE	297.8KB	Share
IMC Immuron Receives AUD $358,280 R&D Tax Concession Refund
24/11/20	PRICE SENSITIVE	216.57KB	Share
IMC US DoD NMRC Reports Positive Response to Vaccine
09/11/20	PRICE SENSITIVE	326.03KB	Share
IMC Immuron Travelers Diarrhea Market Update
12/10/20	PRICE SENSITIVE	333.58KB	Share
IMC Appendix 4E and 2020 Financial Report
01/09/20	PRICE SENSITIVE	3.17MB	Share
IMC Immuron Announces US$20.0 Million Registered Direct Offering
22/07/20	PRICE SENSITIVE	286.41KB	Share
IMC Immuron Reports Neutralizing activity Against SARS-CoV-2
21/07/20	PRICE SENSITIVE	307.03KB	Share
IMC US DoD Receives FDA Guidance on clinical development plans
20/07/20	PRICE SENSITIVE	290.86KB	Share
IMC IMC & CSIRO to produce oral therapeutic for DoD evaluation
19/06/20	PRICE SENSITIVE	328.83KB	Share
IMC Response to ASX Price Query
10/06/20	PRICE SENSITIVE	327.98KB	Share
IMC Pause in Trading
10/06/20	PRICE SENSITIVE	115.07KB	Share
IMC Immuron Global Sales Up 60%
20/04/20	PRICE SENSITIVE	273.25KB	Share
IMC Resignation of Managing Director and cuts amid Covid19
25/03/20	PRICE SENSITIVE	243.36KB	Share
IMC Half Yearly Report and Accounts
26/02/20	PRICE SENSITIVE	2.53MB	Share
IMC North American Travelan sales up 98% to Dec 2019
28/01/20	PRICE SENSITIVE	355.62KB	Share
IMC Immuron Plans IMM-124E Trial to Prevent Travelers Diarrhea
21/11/19	PRICE SENSITIVE	256.63KB	Share
IMC Immuron Receives AUD $0.53M R&D Tax Concession Refund
04/11/19	PRICE SENSITIVE	233KB	Share
IMC Immuron North American Q1 Sales Up 111% YoY
14/10/19	PRICE SENSITIVE	273.95KB	Share
IMC US Defense funds AU$5.5M for Immuron New Gastro Weapon
02/10/19	PRICE SENSITIVE	295.1KB	Share
IMC US Defense Reports Immuron Travelan Targets Cholera
04/09/19	PRICE SENSITIVE	243.34KB	Share
IMC Appendix 4E & Annual Report to shareholders
30/08/19	PRICE SENSITIVE	3.36MB	Share
IMC Immuron Reports Results in SAH Clinical Trial
08/08/19	PRICE SENSITIVE	253.67KB	Share
IMC Underwritten Public Offer
17/07/19	PRICE SENSITIVE	82.1KB	Share
IMC Immuron Prices Underwritten Public Offering of ADSs
17/07/19	PRICE SENSITIVE	185.56KB	Share
IMC Trading Halt
17/07/19	PRICE SENSITIVE	386.27KB	Share
IMC Proposed Public Offer of IMRN ADSs
17/07/19	PRICE SENSITIVE	216.67KB	Share
IMC Immuron North American revenue surges by 52% in FY19
16/07/19	PRICE SENSITIVE	271.01KB	Share
IMC US DoD Reports Results from Travelan Shigellosis Study
12/06/19	PRICE SENSITIVE	243.46KB	Share
IMC Underwritten Public Offer
24/05/19	PRICE SENSITIVE	81.25KB	Share
IMC Preliminary Prospectus Supplement filed with SEC
24/05/19	PRICE SENSITIVE	537.42KB	Share
IMC Immuron Prices Underwritten Public Offering of ADSs
24/05/19	PRICE SENSITIVE	185.41KB	Share
IMC Trading halt
24/05/19	PRICE SENSITIVE	249.9KB	Share
IMC Proposed Public Offer of IMRN ADSs
24/05/19	PRICE SENSITIVE	188.83KB	Share
IMC Immuron Appoints CEO Dr. Gary S. Jacob to Board of Directors
17/04/19	PRICE SENSITIVE	1.02MB	Share
IMC Immuron sales surge by 66% in the Third Quarter of FY19
15/04/19	PRICE SENSITIVE	955.6KB	Share
IMC Immuron Aims to Secure FDA Approval for IMM-124E
11/04/19	PRICE SENSITIVE	887.69KB	Share
IMC Company Update on CDI Clinical Trial and New Strategic Focus
19/03/19	PRICE SENSITIVE	1.21MB	Share
IMC Half Yearly Report and Accounts
28/02/19	PRICE SENSITIVE	872.79KB	Share
IMC Travelan FY19 Update and Expansion into North America
29/01/19	PRICE SENSITIVE	950.8KB	Share
IMC Form F-3
15/01/19	PRICE SENSITIVE	1.25MB	Share
IMC Immuron Receives $1.19M R&D Tax Concession Refund
03/01/19	PRICE SENSITIVE	938.35KB	Share
IMC IMC Appoints Experienced US Based Biotech Executive as CEO
19/11/18	PRICE SENSITIVE	1.08MB	Share
IMC NASH clinical trial presentation & continued revenue growth
09/11/18	PRICE SENSITIVE	848.67KB	Share
IMC US DoD Report Travelan Protects Against Shigella in Primates
05/09/18	PRICE SENSITIVE	1001.92KB	Share
IMC Preliminary Final Report
30/08/18	PRICE SENSITIVE	239.38KB	Share
IMC Immuron Reports Record Revenue
25/07/18	PRICE SENSITIVE	872.69KB	Share
IMC US Department of Defense Research Collaboration Moves Ahead
16/07/18	PRICE SENSITIVE	881.93KB	Share
IMC European Patent Gramted for Nash Treatment
11/07/18	PRICE SENSITIVE	782.89KB	Share
IMC Immuron Announces Board Appointment
26/06/18	PRICE SENSITIVE	815.87KB	Share
IMC Trading Halt
25/06/18	PRICE SENSITIVE	221.37KB	Share
IMC IMC Preclinical Study Reports Reduction in Colitis Symptoms
08/05/18	PRICE SENSITIVE	960.7KB	Share
IMC Travelan Sales Continue to Soar in Third Quarter of FY2018
23/04/18	PRICE SENSITIVE	369.02KB	Share
IMC Immuron Announces A$5.1M Private Placement to U.S. Fund
14/03/18	PRICE SENSITIVE	362.89KB	Share
IMC Immuron Progresses Discussions with Institutional Funds
13/03/18	PRICE SENSITIVE	349.77KB	Share
IMC Trading Halt
12/03/18	PRICE SENSITIVE	215.65KB	Share
IMC Immuron Reports Positive Results in NASH Clinical Trial
08/03/18	PRICE SENSITIVE	402.23KB	Share

REFRESH

1 2

(20min delay)
Last 9.0¢		Change -0.002(2.17%)		Mkt cap ! $20.52M

Open	High	Low	Value	Volume
9.0¢	9.0¢	9.0¢	$10.8K	120K

Buyers (Bids)

No.	Vol.	Price($)
2	50000	9.0¢

Sellers (Offers)

Price($)	Vol.	No.
9.5¢	1500	2

View Market Depth

No.	Vol.	Price($)
2	50000	0.090
1	31751	0.089
2	233688	0.088
1	9309	0.087
1	6849	0.086

Price($)	Vol.	No.
0.095	1500	2
0.097	1500	2
0.098	5714	1
0.100	119000	4
0.105	140757	6

Last trade - 10.04am 21/05/2024 (20 minute delay)


Last 9.0¢		Change -0.002 ( 1.10 %)
Open	High	Low	Volume
9.1¢	9.1¢	9.0¢	42000
Last updated 11.51am 21/05/2024 ?

IMC (ASX) Chart

IMMURON LIMITED - Announcements

Announcements

Buyers (Bids)

Sellers (Offers)

Top Stories